Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses.
Pentagastrin is a cholecystokinin (CCK)-B agonist and laboratory panicogenic agent that produces endocrine (ACTH and cortisol), symptom (anxiety, panic) and cardiovascular (heart rate) responses. Although in vitro data have supported its chemical stability, preliminary data suggested that increasing time between drug preparation and drug infusion could reduce the magnitude of endocrine and symptom responses. The current study examined this possibility. Twenty-one healthy subjects presented at the University of Michigan General Clinical Research Center (GCRC) and had an intravenous catheter inserted. Heart rate, cortisol levels and subjective anxiety were measured before and after pentagastrin and placebo injections. Pentagastrin was prepared either within 60 min of IV infusion (Normal Preparation group) or at least 3.5 h prior to infusion (Early Preparation group). Relative to the Normal Preparation group, Early Preparation subjects had similar heart rate responses but significantly smaller cortisol and subjective anxiety responses. Early preparation of pentagastrin thus appears to weaken endocrine and subjective anxiety responses, highlighting the importance of attending to often overlooked procedural variables (e.g., time between preparation and administration) in studies of this type. The sensitivity of cortisol and anxiety responses to preparation time, but insensitivity of heart rate, is consistent with previous studies suggesting different thresholds of activation for the three response modalities. These differential sensitivities may suggest different and separable CCK-B stimulated pathways for each response, which combine to produce panic, rather than a single, unified CCK-B mediated panicogenic response.
Khan
Samir
S
Trauma, Stress and Anxiety Research Group, Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA.
Briggs
Hedieh
H
Abelson
James Lawrence
JL
D000328:Adult; D001007:Anxiety / Q000097:blood / Q000175:diagnosis; D002766:Cholecystokinin / Q000378:metabolism*; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007262:Infusions, Intravenous; D008297:Male; D016584:Panic Disorder / Q000139:chemically induced*; D010418:Pentagastrin / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D005765:Gastrointestinal Agents; D002766:Cholecystokinin; D010418:Pentagastrin; D006854:Hydrocortisone